Caspase‐8 activation is necessary but not sufficient for tumor necrosis factor‐related apoptosis‐inducing ligand (TRAIL)‐mediated apoptosis in the prostatic carcinoma cell line LNCaP
- 23 May 2002
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 52 (1) , 1-11
- https://doi.org/10.1002/pros.10074
Abstract
BACKGROUND The differential sensitivity of tumor cells to TRAIL-induced apoptosis may be mediated by different intracellular inhibitors of apoptosis, and only a few reports have described the pathway(s) that are activated in response to TRAIL in prostate cells. METHODS LNCaP was transfected with a dominant-negative form of FADD (FADD-DN) and cells were selected in the presence of hygromycin. Cell viability was estimated by calcein assay. Apoptosis was estimated by caspase activation using both fluorogenic substrastes and Western blot analysis of activated caspases. To detect cytochrome c release, mitochondria-free cytosol was prepared and Western blot analysis was performed. RESULTS LNCaP is resistant to TRAIL but TRAIL transiently induces DEVDase activity and activation of caspase-8; caspase-2, -3, -7, and -9 were not activated. Wortmannin, an inhibitor of the PI3K/Akt pathway, converted the phenotype of LNCaP from TRAIL-resistant to -sensitive. In the presence of wortmannin TRAIL induced activation of caspase-2, -3, -7, -8, and -9, as well as dissipation of mitochondrial transmembrane potential and release of cyto-chrome c from mitochondria into the cytosol. In addition, combined TRAIL and wortmannin treatment resulted in cleavage of several proteins: PARP, Akt, p21/WAF1, and MDM2 as well as dephosphorylation of Akt. The proteolysis of p21/WAFI and Akt, which are known survival factors, presumably amplify the apoptotic cascade in LNCaP. Transfection of FADD-DN in LNCaP resulted in inhibition of caspase activation as well as in resistance to combined treatment with TRAIL and wortmannin. CONCLUSIONS These results suggest that caspase-8 activation is necessary but not sufficient for TRAIL-mediated apoptosis and is presumably blocked downstream of caspase-8 by the PI3K/Akt pathway. Prostate 52: 1–11, 2002.Keywords
This publication has 49 references indexed in Scilit:
- Bcl-2 oncoprotein protects the human prostatic carcinoma cell line PC3 from TRAIL-mediated apoptosisOncogene, 2001
- Implication of multiple mechanisms in apoptosis induced by the synthetic retinoid CD437 in human prostate carcinoma cellsOncogene, 2000
- The Novel Receptor TRAIL-R4 Induces NF-κB and Protects against TRAIL-Mediated Apoptosis, yet Retains an Incomplete Death DomainImmunity, 1997
- KILLER/DR5 is a DNA damage–inducible p53–regulated death receptor geneNature Genetics, 1997
- TRAIL-R2: a novel apoptosis-mediating receptor for TRAILThe EMBO Journal, 1997
- An Antagonist Decoy Receptor and a Death Domain-Containing Receptor for TRAILScience, 1997
- The Receptor for the Cytotoxic Ligand TRAILScience, 1997
- Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine FamilyJournal of Biological Chemistry, 1996
- Identification and characterization of a new member of the TNF family that induces apoptosisImmunity, 1995
- FADD, a novel death domain-containing protein, interacts with the death domain of fas and initiates apoptosisCell, 1995